These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 22907939)

  • 1. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS.
    Bosma L; Kragt JJ; Polman CH; Uitdehaag BM
    Mult Scler; 2013 Mar; 19(3):326-33. PubMed ID: 22907939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical scales in progressive MS: predicting long-term disability.
    Bosma LV; Kragt JJ; Knol DL; Polman CH; Uitdehaag BM
    Mult Scler; 2012 Mar; 18(3):345-50. PubMed ID: 21868487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting clinically-relevant changes in progressive multiple sclerosis.
    Bosma LV; Sonder JM; Kragt JJ; Polman CH; Uitdehaag BM
    Mult Scler; 2015 Feb; 21(2):171-9. PubMed ID: 25013153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The search for responsive clinical endpoints in primary progressive multiple sclerosis.
    Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM
    Mult Scler; 2009 Jun; 15(6):715-20. PubMed ID: 19383646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D
    Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.
    Phan-Ba R; Pace A; Calay P; Grodent P; Douchamps F; Hyde R; Hotermans C; Delvaux V; Hansen I; Moonen G; Belachew S
    Neurorehabil Neural Repair; 2011 Sep; 25(7):672-9. PubMed ID: 21436388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese translation and validation of the 12-item Multiple Sclerosis Walking Scale version 2.
    Miyazaki Y; Niino M; Takahashi E; Sato C; Naganuma R; Amino I; Akimoto S; Minami N; Kikuchi S
    Mult Scler Relat Disord; 2024 Sep; 89():105768. PubMed ID: 39003823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.
    Motl RW; Cadavid D; Sandroff BM; Pilutti LA; Pula JH; Benedict RH
    J Neurol Sci; 2013 Dec; 335(1-2):169-73. PubMed ID: 24104065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
    Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM
    Mult Scler; 2010 Jul; 16(7):862-7. PubMed ID: 20488826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
    Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
    Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales.
    Sonder JM; Bosma LV; van der Linden FA; Knol DL; Polman CH; Uitdehaag BM
    Mult Scler; 2012 Feb; 18(2):196-201. PubMed ID: 21908479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.
    Kragt JJ; van der Linden FA; Nielsen JM; Uitdehaag BM; Polman CH
    Mult Scler; 2006 Oct; 12(5):594-8. PubMed ID: 17086905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome.
    Hirst CL; Ingram G; Pickersgill TP; Robertson NP
    Mult Scler; 2012 Aug; 18(8):1152-8. PubMed ID: 22217582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
    Sayao AL; Bueno AM; Devonshire V; Tremlett H;
    Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients.
    Phan-Ba R; Calay P; Grodent P; Delrue G; Lommers E; Delvaux V; Moonen G; Nagels G; Belachew S
    NeuroRehabilitation; 2012; 30(4):261-6. PubMed ID: 22672939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
    van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
    Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls.
    Goldman MD; Marrie RA; Cohen JA
    Mult Scler; 2008 Apr; 14(3):383-90. PubMed ID: 17942508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
    Skov CD; Sørensen CB; Thorning M; Lambertsen KL; Frich LH; Jensen HB; Holsgaard-Larsen A; Nielsen HH
    Mult Scler Relat Disord; 2022 Oct; 66():104034. PubMed ID: 35843140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosis.
    Motl R; Neal W; Backus D; Hebert J; McCully K; Bethoux F; Plummer P; Ng A; Lowman J; Schmidt H; McBurney R; Cutter G
    BMC Neurol; 2024 Oct; 24(1):383. PubMed ID: 39390466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.